市場調査レポート
商品コード
1467605
網膜芽細胞腫治療市場レポート:タイプ別、治療タイプ別、病期分類別、用途別、地域別、2024~2032年Retinoblastoma Treatment Market Report by Type, Treatment Type, Type of Staging, Application, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
網膜芽細胞腫治療市場レポート:タイプ別、治療タイプ別、病期分類別、用途別、地域別、2024~2032年 |
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
世界の網膜芽細胞腫治療市場規模は2023年に28億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけて3.7%の成長率(CAGR)を示し、2032年までに40億米ドルに達すると予測しています。眼科治療に対する医療支出の大幅な増加、副作用の少ない治療法の研究開発(R&D)活動への投資の増加、健康意識の高まりなどが市場を牽引する主要要因です。
網膜芽細胞腫は最も一般的ながんの1つで、一般に小児では5歳以前に発症します。網膜芽細胞腫の症状には、猫の眼反射(cat's eye reflex)または白斑(leukocoria)と呼ばれる瞳孔の白濁があります。網膜芽細胞腫の治療には、さまざまなドラッグデリバリーや化学療法があり、網膜芽細胞腫は初期段階では治癒可能であるため、短期的には一定の効果が得られます。1回目または2回目の化学療法サイクルに続いて、腫瘍の縮小度や眼球内の位置に応じて、さまざまな局所治療を適用することができます。さまざまな治療法を組み合わせることが、最も成功する網膜芽細胞腫の治療法です。手術は網膜から腫瘍を完全に除去するため、網膜芽細胞腫の永久的な治療法です。網膜芽細胞腫の詳細な診断には、超音波試験、CTスキャン、MRI、X線試験、骨スキャンなど、さまざまな画像試験が利用可能です。
眼科治療処置に対する医療支出の大幅な増加は、市場を牽引する重要な要因です。この背景には、若年層における網膜芽細胞腫の罹患率の上昇があります。これに伴い、より副作用の少ない、より効率的な新しい治療戦略に焦点を当てた研究開発(R&D)活動への投資が増加しており、市場に弾みをつけています。さらに、さまざまな種類のがんに対する認識が高まり、診断率や治療率が高まっていることも、大きな成長促進要因となっています。しかし、様々な網膜芽細胞腫治療が入手できないことと、厳しい薬事規制が市場の成長抑制要因となっています。これとは反対に、新薬の上市につながる製品承認の数が増加していることは、市場に明るい展望をもたらしています。これに加えて、網膜芽細胞腫の再発率の増加も、網膜芽細胞腫治療市場に有利な機会を生み出しています。市場はさらに、提携や共同研究、合併・買収(M&A)など、主要な支払者が実施するさまざまな有機的成長戦略によって推進されています。これとは別に、強力なパイプライン医薬品の存在と臨床試験件数の増加が市場の成長を後押ししています。その他、急速な都市化、可処分所得水準の上昇、がん研究の大幅な成長、世界各地の医療インフラの改善なども市場に寄与しています。
The global retinoblastoma treatment market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. A considerable rise in healthcare expenditure for ophthalmic treatment procedures, increasing investments in research and development (R&D) activities on therapies with lower side effects, and the increasing health consciousness represent some of the key factors driving the market.
Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.
A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.
IMARC Group provides an analysis of the key trends in each segment of the global retinoblastoma treatment market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type, treatment type, type of staging, and application.
Non-Hereditary Retinoblastoma
Hereditary Retinoblastoma
The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the type. This includes non-hereditary retinoblastoma and hereditary retinoblastoma. According to the report, non-hereditary retinoblastoma represented the largest segment.
Surgery
Radiation Therapy
Laser Therapy (Photocoagulation)
Cryotherapy
Thermotherapy
Chemotherapy
Opthalmic Artery Infusion Chemotherapy
High-Dose Chemotherapy and Stem Cell Transplant
The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the treatment type. This includes surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, opthalmic artery infusion chemotherapy, and high-dose chemotherapy and stem cell transplant. According to the report, chemotherapy represented the largest segment.
Intraocular Retinoblastoma
Extraocular Retinoblastoma
The report has provided a detailed breakup and analysis of the retinoblastoma treatment market based on the type of staging. This includes intraocular retinoblastoma and extraocular retinoblastoma. According to the report, intraocular retinoblastoma represented the largest segment.
Hospitals
Cancer Institutes
Others
A detailed breakup and analysis of the retinoblastoma treatment market based on the application has also been provided in the report. This includes hospitals, cancer institutes, and others.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report